Article

Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage.

Department of Medicine, Diabetes Center, Hadassah University Hospital, Jerusalem 91120, Israel.
Diabetes/Metabolism Research and Reviews (Impact Factor: 2.97). 01/2005; 21(1):3-14. DOI: 10.1002/dmrr.493
Source: PubMed

ABSTRACT We present multiple findings on derangements in lipid metabolism in type 2 diabetes. The increase in the intracellular deposition of triglycerides (TG) in muscles, liver and pancreas in subjects prone to diabetes is well documented and demonstrated to attenuate glucose metabolism by interfering with insulin signaling and insulin secretion. The obesity often associated with type 2 diabetes is mainly central, resulting in the overload of abdominal adipocytes with TG and reducing fat depot capacity to protect other tissues from utilizing a large proportion of dietary fat. In contrast to subcutaneous adipocytes, the central adipocytes exhibit a high rate of basal lipolysis and are highly sensitive to fat mobilizing hormones, but respond poorly to lipolysis restraining insulin. The enlarged visceral adipocytes are flooding the portal circulation with free fatty acids (FFA) at metabolically inappropriate time, when FFA should be oxidized, thus exposing nonadipose tissues to fat excess. This leads to ectopic TG accumulation in muscles, liver and pancreatic beta-cells, resulting in insulin resistance and beta-cell dysfunction. This situation, based on a large number of observations in humans and experimental animals, confirms that peripheral adipose tissue is closely regulated, performing a vital role of buffering fluxes of FFA in the circulation. The central adipose tissues tend to upset this balance by releasing large amounts of FFA. To reduce the excessive fat outflow from the abdominal depots and prevent the ectopic fat deposition it is important to decrease the volume of central fat stores or increase the peripheral fat stores. One possibility is to downregulate the activity of lipoprotein lipase, which is overexpressed in abdominal relatively to subcutaneous fat stores. This can be achieved by gastrointestinal bypass or gastroplasty, which decrease dietary fat absorption, or by direct means that include surgical removal of mesenteric fat. Indirect treatment consists of the compliant application of drastic lifestyle change comprising both diet and exercise and pharmacotherapy that reduces mesenteric fat mass and activity. The first step should be an attempt to effectively induce a lifestyle change. Next comes pharmacotherapy including acarbose, metformin, PPARgamma, or PPARgammaalpha agonists, statins and orlistat, estrogens in postmenopausal women or testosterone in men. Among surgical procedures, gastric bypass has been proven to produce beneficial results in advance of other surgical techniques, the evidence basis of which still needs strengthening.

2 Followers
 · 
103 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity has become a global problem, and this condition is primarily developed because of an imbalance between energy intake and expenditure. The high complexity involved in the regulation of energy metabolism results from several factors besides endocrine factors. It has been suggested that obesity could be caused by an imbalance in the autonomous nervous system, which could lead to a condition of high parasympathetic activity in counterpart to low sympathetic tonus. High-fat diets (HF) have been used to induce obesity in experimental animals, and their use in animals leads to insulin resistance, hyperinsulinaemia and high parasympathetic activity, among other disorders. The aim of this work was to evaluate the effects of a vagotomy performed at the initiation of a HF during two different periods of life, weaning and adulthood. The vagotomy reduced parasympathetic activity (-32% and -51% in normal fat-fed and -43% and -55% in HF-fed rats; p<0.05) and fat depots (-17% and -33%, only in HF-fed rats; p<0.05). Both HF-fed rats exhibited fasting hyperinsulinaemia (+5-fold in younger and +3-fold in older rats; p<0.05); however, vagotomy corrected it, only in younger rats, and a similar effect was also observed during the glucose tolerance test. The insulin resistance exhibited by the HF-fed groups did not alter in the vagotomised rats. We suggest that the vagus nerve, in addition to the important role of the parasympathetic activity, partially contributes to obesity conditions and that non-vagal pathways may be involved along with the imbalanced autonomous nervous system. This article is protected by copyright. All rights reserved.
    Experimental Physiology 11/2014; 100(1). DOI:10.1113/expphysiol.2014.082982 · 2.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Natural product Hypericum perforatum L. has been used in folk medicine to improve mental performance. However, the effect of H. perforatum L. on metabolism is still unknown. In order to test whether H. perforatum L. extract (EHP) has an effect on metabolic syndrome, we treated diet induced obese (DIO) C57BL/6J mice with the extract. The chemical characters of EHP were investigated with thin-layer chromatography, ultraviolet, high-performance liquid chromatography (HPLC), and HPLC-mass spectrometry fingerprint analysis. Oral glucose tolerance test (OGTT), insulin tolerance test (ITT), and the glucose infusion rate (GIR) in hyperinsulinemic–euglycemic clamp test were performed to evaluate the glucose metabolism and insulin sensitivity. Skeletal muscle was examined for lipid metabolism. The results suggest that EHP can significantly improve the glucose and lipid metabolism in DIO mice. In vitro, EHP inhibited the catalytic activity of recombinant human protein tyrosine phosphatase 1B (PTP1B) and reduced the protein and mRNA levels of PTP1B in the skeletal muscle. Moreover, expressions of genes related to fatty acid uptake and oxidation were changed by EHP in the skeletal muscle. These results suggest that EHP may improve insulin resistance and lipid metabolism in DIO mice. Copyright © 2014 John Wiley & Sons, Ltd.
    Phytotherapy Research 09/2014; 29(1). DOI:10.1002/ptr.5230 · 2.40 Impact Factor
  • Source
    Journal of medicinal plant research 06/2012; 6(23). DOI:10.5897/JMPR12.040 · 0.88 Impact Factor